In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Natco Pharma Limited

http://www.natcopharma.co.in

Latest From Natco Pharma Limited

Spluttering US Generics Landscape Shows Signs Of Promise In Q2

High-value launches and an improving broader landscape for generic pricing provided a fillip for some US generics manufacturers in the second quarter, although others disclosed that they were still weathering the storm as the end of the year approaches.

Generic Drugs Commercial

Spluttering US Generics Landscape Shows Signs Of Promise In Q2

High-value launches and an improving broader landscape for generic pricing provided a fillip for some US generics manufacturers in the second quarter, although others disclosed that they were still weathering the storm as the end of the year approaches.

Generic Drugs Commercial

Zydus To Slice Into Shrinking Revlimid Pie ‘In Near Term’ As Asacol Revenues Erode

Zydus is set to join Natco in chipping away at BMS’ blockbuster Revlimid with its generic version, probably from Q2 while Aurobindo expects to launch by FY24. Revenues from this drug are expected to offset erosion of generic Asacol revenues even as Zydus expects volume growth and new launches to help grow its US business.

Strategy Generic Drugs

Zydus To Slice Into Shrinking Revlimid Pie ‘In Near Term’ As Asacol Revenues Erode

Zydus is set to join Natco in chipping away at BMS’ blockbuster Revlimid with its generic version, probably from Q2 while Aurobindo expects to launch by FY24. Revenues from this drug are expected to offset erosion of gAsacol revenues even as Zydus expects volume growth and new launches to help grow its US business

Commercial Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
UsernamePublicRestriction

Register